803 related articles for article (PubMed ID: 34080271)
1. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival.
Jakubíková M; Týblová M; Tesař A; Horáková M; Vlažná D; Ryšánková I; Nováková I; Dolečková K; Dušek P; Piťha J; Voháňka S; Bednařík J
Eur J Neurol; 2021 Oct; 28(10):3418-3425. PubMed ID: 34080271
[TBL] [Abstract][Full Text] [Related]
2. TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE.
Županić S; Lazibat I; Rubinić Majdak M; Jeličić M
Acta Clin Croat; 2022 Feb; 60(3):496-509. PubMed ID: 35282492
[TBL] [Abstract][Full Text] [Related]
3. The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
Bakirtzis C; Boziki MK; Karakasi MV; Moysiadis T; Grigoriadis N
Muscle Nerve; 2023 May; 67(5):412-416. PubMed ID: 36814101
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome.
Ramaswamy SB; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):361-364. PubMed ID: 32508329
[TBL] [Abstract][Full Text] [Related]
5. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.
Županić S; Perić Šitum M; Majdak M; Karakaš M; Bašić S; Sporiš D
Acta Neurol Belg; 2021 Aug; 121(4):1039-1044. PubMed ID: 33797054
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 pandemic year in a sample of Polish myasthenia gravis patients: an observational study.
Rzepiński Ł; Zawadka-Kunikowska M
Neurol Neurochir Pol; 2022; 56(1):61-67. PubMed ID: 34346049
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 infection in myasthenia gravis: Clinical course and outcomes.
Thomas EV; Bou G; Barton S; Hutto S; Garcia-Santibanez R
Muscle Nerve; 2023 Aug; 68(2):171-175. PubMed ID: 37326164
[TBL] [Abstract][Full Text] [Related]
8. Use of Remdesivir in Myasthenia gravis and COVID-19.
Peters BJ; Rabinstein AA; DuBrock HM
Pharmacotherapy; 2021 Jun; 41(6):546-550. PubMed ID: 33835512
[TBL] [Abstract][Full Text] [Related]
9. Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID-19.
Gungor Tuncer O; Deymeer F
Muscle Nerve; 2022 Apr; 65(4):447-452. PubMed ID: 35040147
[TBL] [Abstract][Full Text] [Related]
10. Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
Stascheit F; Grittner U; Hoffmann S; Mergenthaler P; Schroeter M; Ruck T; Pawlitzki M; Blaes F; Kaiser J; Schara U; Della-Marina A; Thieme A; Hagenacker T; Jacobi C; Berger B; Urban PP; Knop KC; Schalke B; Lee DH; Kalischewski P; Wiendl H; Meisel A
J Neurol; 2023 Jan; 270(1):1-12. PubMed ID: 36166068
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 in patients with myasthenia gravis: Epidemiology and disease course.
Businaro P; Vaghi G; Marchioni E; Diamanti L; Arceri S; Bini P; Colombo E; Cosentino G; Alfonsi E; Costa A; Ravaglia S; Mallucci G; Ballante E; Franciotta D; Gastaldi M
Muscle Nerve; 2021 Aug; 64(2):206-211. PubMed ID: 34031902
[TBL] [Abstract][Full Text] [Related]
12. Clinical course and outcome of Covid-19 in patients with myasthenia gravis.
Aktoz G; Boz C; Zengin S; Okumus AC; Horozoglu H; Kara F; Oral E; Ozmenoglu M
Neurol Res; 2023 Jun; 45(6):583-589. PubMed ID: 36681934
[TBL] [Abstract][Full Text] [Related]
13. Comment on "Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic status and survival" by Jakubíková et al.
Galassi G; Marchioni A
Eur J Neurol; 2022 Jan; 29(1):e5-e6. PubMed ID: 34586695
[No Abstract] [Full Text] [Related]
14. Myasthenia gravis and COVID-19: A case series and comparison with literature.
Saied Z; Rachdi A; Thamlaoui S; Nabli F; Jeridi C; Baffoun N; Kaddour C; Belal S; Ben Sassi S
Acta Neurol Scand; 2021 Sep; 144(3):334-340. PubMed ID: 33914898
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review.
Rodrigues CL; de Freitas HC; Lima PRO; de Oliveira Junior PH; Fernandes JMA; D'Almeida JAC; Nóbrega PR
Neurol Sci; 2022 Apr; 43(4):2271-2276. PubMed ID: 35039987
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival.
Jakubikova M; Tyblova M; Tesar A; Magda H; Daniela V; Irena R; Iveta N; Kristyna D; Pavel D; Jiri P; Stanislav V; Josef B
Eur J Neurol; 2022 Jan; 29(1):e7-e8. PubMed ID: 34699086
[No Abstract] [Full Text] [Related]
17. Respiratory dysfunction as first presentation of myasthenia gravis misdiagnosed as COVID-19.
Scopelliti G; Osio M; Arquati M; Pantoni L
Neurol Sci; 2020 Dec; 41(12):3419-3421. PubMed ID: 33068195
[TBL] [Abstract][Full Text] [Related]
18. Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.
Gamez J; Gamez A; Carmona F
Muscle Nerve; 2022 Nov; 66(5):612-617. PubMed ID: 36029224
[TBL] [Abstract][Full Text] [Related]
19. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
; Jacob S; Muppidi S; Guidon A; Guptill J; Hehir M; Howard JF; Illa I; Mantegazza R; Murai H; Utsugisawa K; Vissing J; Wiendl H; Nowak RJ
J Neurol Sci; 2020 May; 412():116803. PubMed ID: 32247193
[No Abstract] [Full Text] [Related]
20. COVID-19 in Patients with Myasthenia Gravis: Mechanisms of Respiratory Failure.
Murthy JMK; Gutta AK; Yerasu MR; Boorgu SK; Osman S; Jaiswal SK; Pidaparthi L; Gudavalli BP
Neurol India; 2021; 69(6):1772-1776. PubMed ID: 34979686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
